Sarepta Therapeutics, Inc.NASDAQ: SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

· Issued by Sarepta Therapeutics, Inc.

Summary by 6ix AI

Sarepta Therapeutics, a developer of genetic medicines for rare diseases, granted equity awards on July 28, 2026 to Michael Severino, M.D., as a material inducement to employment as Chief Executive Officer. The awards fall under its 2024 Employment Commencement Incentive Plan, as amended, and were approved in accordance with Nasdaq Listing Rule 5635(4), which covers inducement grants.

Key details

  • Dr. Severino received options to buy 2,224,342 shares of Sarepta common stock and 756,104 restricted stock units (rights to receive shares once they vest).
  • The options have an exercise price of $17.74 per share, equal to a 15% premium to Sarepta's closing share price on July 28, 2026, the grant date.
  • One-fourth of the options vest on the first anniversary of the grant date, then 1/48th vest monthly, so they are fully vested on the fourth anniversary.
  • One-fourth of the restricted stock units vest on each yearly anniversary of the grant date, so they are fully vested on the fourth anniversary.

What’s still pending

  • Vesting of both the options and the restricted stock units is generally subject to Dr. Severino's continued employment with Sarepta on each vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

CAMBRIDGE - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta.

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(4).

Dr. Severino received options to purchase 2,224,342 shares of Sarepta's common stock ('Options'), and 756,104 restricted stock units ('RSUs'). The options have an exercise price of $17.74 per share, which is equal to a 15% premium to the closing price of Sarepta's common stock on July 28, 2026 (the 'Grant Date'). One-fourth of Dr. Severino's Options will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of Dr. Severino's Options will vest monthly, such that the Options will be fully vested on the fourth anniversary of the Grant Date, in each case, generally subject to Dr. Severino's continued employment with Sarepta on such vesting dates. One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to Dr. Severino will be fully vested on the fourth anniversary of the Grant Date, generally subject to Dr. Severino's continued employment with Sarepta on such vesting date.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

Contact:

Ian Estepan

Tel: 617-274-4052

Email: [email protected]

Tam Thornton

Tel: 617-803-3825

Email: [email protected]

Tracy Sorrentino

Tel: 617-301-8566

Email: [email protected]

(C) 2026 Electronic News Publishing, source ENP Newswire

Sarepta Therapeutics, Inc. on 6ix

Story so far

Earlier from Sarepta Therapeutics

Later from Sarepta Therapeutics

All Sarepta Therapeutics news releases